The phagocytosis of FAP+ cells specifically by FAP-CAR-Ms was observed in vitro, and in vivo animal experiments also confirmed that an intravenous infusion of FAP-CAR-Ms could effectively ameliorate CCl4-induced liver fibrosis in mice, indicating its therapeutic potential in the treatment of liver fibrosis [30]. This evidence concerns the gene MTR and Hepatic fibrosis.